

LAW OFFICES OF
ALBERT WAI-KIT CHAN, PLLC
WORLD PLAZA, SUITE 804
141-07 20TH AVENUE
WHITESTONE, NEW YORK 11357

RECEIVED
CENTRAL FAX CENTER

AUG 07 2007

718-788-1000
FAX 718 357-8615
CHANK@KITCHANLAW.COM

PLEASE DELIVER THE FOLLOWING PAGES

TO : SUPERVISING EXAMINER JOSEPH WOITACH

COMPANY : UNITED STATES PATENT AND TRADEMARK OFFICE

FAX NO. : (571) 273-8300

FROM : ALBERT WAI-KIT CHAN/dl

RE : SUPPLEMENTAL RESPONSE TO THE JUNE 28, 2007 OFFICE ACTION, U.S. Serial No. 10/738,423, Filed December 16, 2003 - Our Dkt. #873-Z-US

TOTAL NUMBER OF PAGES, INCLUDING COVER SHEET: 18

DATE : August 7, 2007

* IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS POSSIBLE TO (718) 799-1000.

Message

Applicants : Ivan C. KING and Li Mou ZHENG
Client : VION Pharmaceuticals, Inc.
Date : August 7, 2007

File No.: 873-Z-US

Dear Supervisor Joseph Woitach,

Please see the enclosed.

I hereby certify that the enclosed paper is being facsimile transmitted to: Supervising Examiner Joseph Woitach, Ph.D., United States Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 at (571) 273-8300 on the date shown below.

Albert Wai-Kit Chan 8/7/07
Albert Wai-Kit Chan, Ph.D. Date
Reg. No. 36,479

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED SOLELY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENT(S) NAMED ABOVE. THIS TRANSMISSION MAY CONTAIN INFORMATION THAT IS CONFIDENTIAL UNDER THE CLIENT AND ATTORNEY RELATIONSHIP. IF THE READER OF THIS MESSAGE IS NOT A DESIGNATED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO A DESIGNATED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, OR IF UPON READING THIS DOCUMENT YOU HAVE REASON TO BELIEVE THAT THE DOCUMENT WAS INADVERTENTLY SENT TO YOU, PLEASE NOTIFY US IMMEDIATELY BY COLLECT TELEPHONE CALL AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

BEST AVAILABLE COPY

Dkt #873-Z-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ivan C. KING, and Li Mou ZHENG

U.S. Serial No. : 10/738,423

Confirmation No. : 8783

Filed : December 16, 2003

Art Unit : 1633

Examiner : Qian Janice Li

For : COMPOSITIONS AND METHODS FOR TUMOR-
TARGETED DELIVERY OF EFFECTOR MOLECULESRECEIVED
CENTRAL FAX CENTER

AUG 07 2007

Law Offices of Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

August 7, 2007

Supervisor Joseph Weitach, Ph.D.
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL RESPONSE TO THE JUNE 28, 2007 OFFICE ACTION

This communication is a Supplemental Response to the June 28, 2007 OFFICE ACTION, which was filed on July 20, 2007. This communication calls attention to the Supervising Examiner, Supervisor Joseph Weitach, Ph.D.

BEST AVAILABLE COPY

Applicants : Ivan C. KING and Li Mou ZHENG
U.S. Serial No.: 10/738,423
Filed : December 16, 2003
Page : 2

Attached please find a copy of the amendment that was filed on July 20, 2007 in response to the most recent office action in this case. Applicants respectfully request Supervisor Woitach's comments relating to the sufficiency of the arguments provided in response to the outstanding rejection under 35 U.S.C. § 103(a). It is the applicants' position that Examiner Qian Janice Li's application of the prior art cannot reasonably be found sufficient to establish *prima facie* obviousness under § 103(a).

It should be noted that applicants are certain that Dr. Li is proceeding in good faith based on her interpretation of the law. Similarly, applicants also believe in good faith that Dr. Li's rationale for maintaining the rejection reveals questionable interpretations of the relevant case law and MPEP guidelines. In brief, Dr. Li's rationale for maintaining the rejection is largely based on a nonspecific and generalized motivation to improve cancer treatment, a motivation shared by all.

Specifically, the rejection fails to describe the specific modifications of the combined references that lead to the claimed subject matter. It is also respectfully submitted that the comments in the rejection tend to mischaracterize or ignore attempts to demonstrate that manner in which the office action is inconsistent with longstanding MPEP guidelines for establishing a *prima facie* case of obviousness. For these reasons, applicants respectfully request Supervisor Woitach's input in this matter.

BEST AVAILABLE COPY

Applicants : Ivan C. KING and Li Mou ZHENG
U.S. Serial No.: 10/738,423
Filed : December 16, 2003
Page : 3

If a telephone interview would be of assistance in advancing the prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below. If any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai-Kit Chan

Albert Wai-Kit Chan, Ph.D.
Registration No. 36,479
Attorney for Applicant(s)
Law Offices of
Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
E-mail: chunk@kitchanlaw.com

Dkt #873-Z-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Ivan C. KING, and Li Mou ZHENG

U.S. Serial No. : 10/738,423

Confirmation No. : 8783

Filed : December 16, 2003

Art Unit : 1633

Examiner : ~~Qian Janice Li~~For : COMPOSITIONS AND METHODS FOR TUMOR-
TARGETED DELIVERY OF EFFECTOR MOLECULESLaw Offices of Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

July 20, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Madam:

AMENDMENT IN RESPONSE TO JUNE 28, 2007 OFFICE ACTION

This communication is being submitted in response to the June 28, 2007 Office Action issued by the United States Patent and Trademark Office (USPTO) in connection with the above-identified application. The shortened period for response is three (3) months from the date of mailing of the Office Action, i.e., by September 28, 2007. Accordingly, this Amendment is timely filed.

BEST AVAILABLE COPY

Applicants : Ivan C. KING and Li Mou ZHENG
U.S. Serial No.: 10/738,423
Filed : December 16, 2003
Page : 2

Claim Amendment Fee Calculation

	Claims remaining after amendment		Highest No. Previously Paid	Extra	Rate (Large Entity)	Rate (Small Entity)	Additional Fee
Total	12	-	20	0	X \$50.00	X \$25.00	\$0.00
Ind.	2	-	4	0	X \$200.00	X \$100.00	\$0.00

Amendment to the claims begin on page 3 of this communication

Remarks begin on page 5 of this communication

Conclusion begin on page 15